Praziquantel for schistosomiasis: Single-drug metabolism revisited, mode of action, and resistance

Nuno Vale*, Maria João Gouveia, Gabriel Rinaldi, Paul J. Brindley, Fátima Gärtner, José M.Correia Da Costa

*Awdur cyfatebol y gwaith hwn

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygl adolyguadolygiad gan gymheiriaid

227 Dyfyniadau(SciVal)


Schistosomiasis, a major neglected tropical disease, affects more than 250 million people worldwide. Treatment of schistosomiasis has relied on the anthelmintic drug praziquantel (PZQ) for more than a generation. PZQ is the drug of choice for the treatment of schistosomiasis; it is effective against all major forms of schistosomiasis, although it is less active against juvenile than mature parasites. A pyrazino-isoquinoline derivative, PZQ is not considered to be toxic and generally causes few or transient, mild side effects. Increasingly, mass drug administration targeting populations in sub-Saharan Africa where schistosomiasis is endemic has led to the appearance of reduced efficacy of PZQ, which portends the selection of drugresistant forms of these pathogens. The synthesis of improved derivatives of PZQ is attracting attention, e.g., in the (i) synthesis of drug analogues, (ii) rational design of pharmacophores, and (iii) discovery of new compounds from large-scale screening programs. This article reviews reports from the 1970s to the present on the metabolism and mechanism of action of PZQ and its derivatives against schistosomes.

Iaith wreiddiolSaesneg
Rhif yr erthygle02582
CyfnodolynAntimicrobial Agents and Chemotherapy
Rhif cyhoeddi5
Dynodwyr Gwrthrych Digidol (DOIs)
StatwsCyhoeddwyd - Mai 2017
Cyhoeddwyd yn allanolIe

Ôl bys

Gweld gwybodaeth am bynciau ymchwil 'Praziquantel for schistosomiasis: Single-drug metabolism revisited, mode of action, and resistance'. Gyda’i gilydd, maen nhw’n ffurfio ôl bys unigryw.

Dyfynnu hyn